This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Efuet, E. T. Articles by Keyomarsi, K. Search for Related Content PubMed PubMed Citation Articles by Efuet, E. T. Articles by Keyomarsi, K.

Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G₁ Arrest by Targeting the Proteasome

¹ Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center and ² Cancer Biology Program, Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, Texas

Requests for reprints: Khandan Keyomarsi, Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Box 66, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-4845; Fax: 713-794-5369; E-mail: kkeyomar{at}mail.mdanderson.org.

Isoprenoid inhibitors are being evaluated as agents for the treatment of cancer. Their antitumor activity is attributed to inhibition of post-translational modification of Ras, which is crucial for its translocation and attachment to the plasma membrane, and ultimate involvement in signal transduction. However, whether blocking of Ras is solely responsible for the observed antitumor activity is unresolved. In this report, we propose an alternate mechanism. Using breast tumor models, we show that agents possessing a lactone moiety, including statins (such as lovastatin) and the isoprenoid inhibitors (such as FTI-277 and GGTI-298), mediate their cell cycle inhibitory activities by blocking the chymotrypsin activity of the proteasome in vitro. This results in the accumulation of cyclin-dependent kinase inhibitors p21 and p27 with subsequent G₁ arrest. Cells devoid of p21 were refractory to the growth-inhibitory activity of lovastatin, FTI-277, and GGTI-298. However, in these p21 null cells, isoprenylation of key substrates of farnesyl transferase (such as Ras) and of geranylgeranyl transferase (such as RAP-1) were inhibited by FTI-277 and GGTI-298, respectively, suggesting that although both these isoprenoid inhibitors reached and inhibited their intended targets, inhibition of the isoprenylation of Ras and RAP-1A are not sufficient to mediate G₁ arrest. We also show that the cell cycle effects can be attributed to the functional lactone moiety of the aforementioned agents. Collectively, our data suggest that FTI and GGTI and other agents containing an active lactone moiety mediate G₁ arrest via inhibition of the proteasome and up-regulation of p21, independent of the inhibition of isoprenylation of Ras or RAP-1. (Cancer Res 2006; 66(2): 1040-51)

This article has been cited by other articles:

				J. W. Wojtkowiak, F. Fouad, D. T. LaLonde, M. D. Kleinman, R. A. Gibbs, J. J. Reiners Jr., R. F. Borch, and R. R. Mattingly Induction of Apoptosis in Neurofibromatosis Type 1 Malignant Peripheral Nerve Sheath Tumor Cell Lines by a Combination of Novel Farnesyl Transferase Inhibitors and Lovastatin J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 1 - 11. [Abstract] [Full Text] [PDF]

				W. R. Farwell, R. E. Scranton, E. V. Lawler, R. A. Lew, M. T. Brophy, L. D. Fiore, and J. M. Gaziano The Association Between Statins and Cancer Incidence in a Veterans Population J Natl Cancer Inst, January 16, 2008; 100(2): 134 - 139. [Abstract] [Full Text] [PDF]

				A. Hoque, H. Chen, and X.-c. Xu Statin Induces Apoptosis and Cell Growth Arrest in Prostate Cancer Cells Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 88 - 94. [Abstract] [Full Text] [PDF]

				S. G. Sala, U. Munoz, F. Bartolome, F. Bermejo, and A. Martin-Requero HMG-CoA Reductase Inhibitor Simvastatin Inhibits Cell Cycle Progression at the G1/S Checkpoint in Immortalized Lymphocytes from Alzheimer's Disease Patients Independently of Cholesterol-Lowering Effects J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 352 - 359. [Abstract] [Full Text] [PDF]

				C. L. Navarro, P. Cau, and N. Levy Molecular bases of progeroid syndromes Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R151 - R161. [Abstract] [Full Text] [PDF]